Trial Outcomes & Findings for The LoBAG Diet and Type 2 Diabetes Mellitus (NCT NCT02717078)

NCT ID: NCT02717078

Last Updated: 2024-07-26

Results Overview

Marker of blood sugar control

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

48 participants

Primary outcome timeframe

Week 12

Results posted on

2024-07-26

Participant Flow

Participant milestones

Participant milestones
Measure
LoBAG Diet
Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Control Diet
Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Overall Study
STARTED
24
24
Overall Study
COMPLETED
20
18
Overall Study
NOT COMPLETED
4
6

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The LoBAG Diet and Type 2 Diabetes Mellitus

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
LoBAG Diet
n=24 Participants
Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Control Diet
n=24 Participants
Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Total
n=48 Participants
Total of all reporting groups
Age, Continuous
59.0 years
STANDARD_DEVIATION 9.1 • n=99 Participants
55.8 years
STANDARD_DEVIATION 11.5 • n=107 Participants
57.4 years
STANDARD_DEVIATION 10.3 • n=206 Participants
Sex: Female, Male
Female
12 Participants
n=99 Participants
18 Participants
n=107 Participants
30 Participants
n=206 Participants
Sex: Female, Male
Male
12 Participants
n=99 Participants
6 Participants
n=107 Participants
18 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=99 Participants
4 Participants
n=107 Participants
7 Participants
n=206 Participants
Race (NIH/OMB)
White
21 Participants
n=99 Participants
16 Participants
n=107 Participants
37 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Week 12

Marker of blood sugar control

Outcome measures

Outcome measures
Measure
LoBAG Diet
n=20 Participants
Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Control Diet
n=18 Participants
Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Change in Hemoglobin A1c From Baseline to Week 12
6.6 percentage
Standard Deviation 0.6
7.2 percentage
Standard Deviation 0.8

SECONDARY outcome

Timeframe: Week 12

Weight in pounds

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

Blood draw

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

Blood draw

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline

A meal will be provided, and blood drawn at regular intervals for 4 hours following the meal

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

A meal will be provided, and blood drawn at regular intervals for 4 hours following the meal

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

A marker of blood sugar control, similar to hemoglobin A1c

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

Blood draw

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

Questionnaire to determine satisfaction with current diabetes treatment, scored 0 (very dissatisfied) to 36 (very satisfied)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline

The human gut microbiome refers to the bacteria, fungi, and viruses that inhabit the human intestine. Participants will be asked to collect a small sample of stool on a swab. Collection will be done at home.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 6

The human gut microbiome refers to the bacteria, fungi, and viruses that inhabit the human intestine. Participants will be asked to collect a small sample of stool on a swab. Collection will be done at home.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

The human gut microbiome refers to the bacteria, fungi, and viruses that inhabit the human intestine. Participants will be asked to collect a small sample of stool on a swab. Collection will be done at home.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline

Urine sample

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 3

Urine sample

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 6

Urine sample

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 9

Urine sample

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

Urine sample

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline

Meal record for 3 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 6

Meal record for 3 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 12

Meal record for 3 days

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 9

Interview to review meals consumed in previous 24 hours

Outcome measures

Outcome data not reported

Adverse Events

LoBAG Diet

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Control Diet

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
LoBAG Diet
n=24 participants at risk
Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
Control Diet
n=24 participants at risk
Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks. Diet Therapy: The intervention for both study groups will be a change in diet.
General disorders
Nausea
4.2%
1/24 • Number of events 1 • 12 weeks
0.00%
0/24 • 12 weeks
Nervous system disorders
tingling/neuropathy symptoms
0.00%
0/24 • 12 weeks
4.2%
1/24 • Number of events 1 • 12 weeks
Gastrointestinal disorders
constipation
4.2%
1/24 • Number of events 1 • 12 weeks
0.00%
0/24 • 12 weeks
Ear and labyrinth disorders
ear infection
4.2%
1/24 • Number of events 1 • 12 weeks
0.00%
0/24 • 12 weeks
General disorders
arm pain
0.00%
0/24 • 12 weeks
4.2%
1/24 • Number of events 1 • 12 weeks
Renal and urinary disorders
kidney stone
0.00%
0/24 • 12 weeks
4.2%
1/24 • Number of events 1 • 12 weeks
General disorders
back injury
4.2%
1/24 • Number of events 1 • 12 weeks
0.00%
0/24 • 12 weeks

Additional Information

Anne Bantle

University of Minnesota

Phone: 612-625-8673

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place